title: Current status of nanotechnology approaches for cardiovascular disease: a personal perspective.
abstract: Nanotechnology is poised to have an increasing impact on cardiovascular health in coming years. Diagnostically, multiplexed point-of-care devices will enable rapid genotyping and biomarker measurement to optimize and tailor therapies for the individual patient. Nanoparticle-based molecular imaging agents will take advantage of targeted agents to provide increased insight into disease pathways rather then simply providing structural and functional information. Drug delivery will be impacted by targeting of nanoparticle-encapsulated drugs to the site of action, increasing the effective concentration and decreasing systemic dosage and side effects. Controlled and tailored release of drugs from polymers will improve control of pharmacokinetics and bioavailability. The application of nanotechnology to tissue engineering will facilitate the fabrication of better tissue implants in vitro, and provide scaffolds to promote regeneration in vivo taking advantage of the body's own repair mechanisms. Medical devices will benefit from the development of nanostructured surfaces and coatings to provide better control of thrombogenicity and infection. Taken together, these new technologies have enormous potential for improving the diagnosis and treatment of cardiovascular diseases.
authors.affiliation: National Heart, Lung, and Blood Institute, 6701 Rockledge Drive, Bethesda, MD 20892-7940, USA. db225a@nih.gov
authors.forename: Denis B
authors.initials: DB
authors.lastname: Buxton
mesh_terms: D015374:Biosensing Techniques / Q000295:instrumentation / Q000639:trends*; D002318:Cardiovascular Diseases / Q000175:diagnosis* / Q000628:therapy*; D004337:Drug Carriers / Q000138:chemical synthesis*; D005544:Forecasting; D050997:Nanomedicine / Q000295:instrumentation / Q000639:trends*; D053758:Nanoparticles / Q000737:chemistry / Q000627:therapeutic use*; D014481:United States
chemical_list: D004337:Drug Carriers